These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
318 related items for PubMed ID: 19407299
21. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G. Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550 [Abstract] [Full Text] [Related]
22. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer. Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567 [Abstract] [Full Text] [Related]
27. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Ageno W. Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271 [Abstract] [Full Text] [Related]
28. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Turun S, Banghua L, Yuan Y, Zhenhui L, Ying N, Jin C. Thromb Res; 2011 Jun; 127(6):525-34. PubMed ID: 21397931 [Abstract] [Full Text] [Related]
29. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Rosencher N, Llau JV, Mueck W, Loewe A, Berkowitz SD, Homering M. Acta Anaesthesiol Scand; 2013 May; 57(5):565-72. PubMed ID: 23336294 [Abstract] [Full Text] [Related]
30. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. Fuji T, Ochi T, Niwa S, Fujita S. J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459 [Abstract] [Full Text] [Related]
35. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators. Circulation; 2007 Jul 10; 116(2):180-7. PubMed ID: 17576867 [Abstract] [Full Text] [Related]
36. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Laux V, Perzborn E, Kubitza D, Misselwitz F. Semin Thromb Hemost; 2007 Jul 10; 33(5):515-23. PubMed ID: 17629849 [Abstract] [Full Text] [Related]
37. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. Lassen MR, Gent M, Kakkar AK, Eriksson BI, Homering M, Berkowitz SD, Turpie AG. J Bone Joint Surg Br; 2012 Nov 10; 94(11):1573-8. PubMed ID: 23109641 [Abstract] [Full Text] [Related]
40. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R. Eur J Orthop Surg Traumatol; 2013 May 10; 23(4):481-6. PubMed ID: 23412293 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]